Our portfolio

To date, CEPI has established multiple partnership agreements, reflecting a potential investment of up to $456 million. Through these collaborations, we're supporting the development of a wide range of vaccine candidates.

We also have number of additional partnerships under negotiation. These partnership agreements represent the start of CEPI’s product development portfolio. See below current details of our vaccine portfolio.

PRODUCT DEVELOPERS
  • All
  • Colorado State University
  • CureVac
  • IDT Biologika
  • Imperial College London
  • Inovio Pharmaceuticals
  • International AIDS Vaccine Initiative
  • Janssen Vaccines & University of Oxford
  • Profectus Biosciences, Emergent Biosolutions & PATH
  • Public Health Vaccines
  • Themis Bioscience
  • University of Queensland
  • University of Tokyo
  • Valneva SE
  • Wageningen Bioveterinary Research
DISEASE
  • All
  • Chikungunya
  • Lassa virus
  • Marburg virus
  • MERS coronavirus
  • Nipah virus
  • Rift Valley Fever
VACCINE TYPE
  • All
  • Live attenuated vaccine
  • Nucleic acid
  • Recombinant protein
  • Recombinant viral vector
PHASE
  • All
  • Phase 1
  • Phase 2
  • Phase 3
  • Preclinical
{{ mob.finishButton }}
Filter by product developers:
Filter by disease:
Filter by vaccine type:
Filter by phase:

{{ dev['funding_title'] }}

{{ dev['funding'] }}

{{ d['disease'] }}
{{ d['vaccine_type'] }}
{{ d['trial_title'] }}
{{ d['trial'] }}
{{ d['phase'] }}
?
?

{{ d['description'] }}

N/A
No result